Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) just unveiled an announcement.
Structure Therapeutics Inc. has announced strategic changes to its executive team, with Dr. Blai Coll stepping into the Chief Medical Officer role, succeeding Dr. Mark Bach following his planned departure. Dr. Coll brings a wealth of experience from his previous position as Vice President of Clinical Development, complemented by his tenure at Amgen. Additionally, Ashley Hall has been named the new Chief Development Officer, bringing her extensive background in regulatory strategy and clinical development from her previous roles at Reneo Pharmaceuticals and Esperion Therapeutics. These leadership appointments are poised to drive the company’s clinical developments, including the advancement of their novel oral small molecule therapeutics.
Learn more about GPCR stock on TipRanks’ Stock Analysis page.
